Diabetes Wearable-Maker Handily Beats Earnings Views, Hikes Sales Guide

Diabetes wearables-maker Dexcom topped third-quarter earnings forecasts Thursday and reported in-line sales. Dexcom stock was little moved.

Investors Business Daily • 3 hours ago

What DexCom (DXCM) Said on Its Q3 Earnings Call

DexCom NASDAQ: DXCM reported third-quarter 2026 revenue of $1.34 billion, up 11% from a year earlier on both a reported and organic basis, as U.S. growth, market-share gains and manufacturing improvements supported higher profitability.

MarketBeat • 31 minutes ago

Dexcom Reports Third Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2026 Financial Results.

Business Wire • 4 hours ago

DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates

DexCom (DXCM) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.61 per share a year ago.

Zacks Investment Research • 2 hours ago

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November

BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes. Offering up to 15.5 days of wear,2 Dexcom G7 15 Day combines industry leading sensor duration with best-in-class accuracy,1 giving Canadians living with diabetes more time between sensor changes and.

Business Wire • Oct 28, 2026

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire • Oct 27, 2026

DexCom Gears Up to Report Q3 Results: How to Play the Stock?

DXCM Q3 earnings are likely to benefit from CGM adoption, G7 15 Day uptake and wider reimbursement amid tougher international comparisons.

Zacks Investment Research • Oct 26, 2026

7 healthcare stocks that stand out as investors pay up for the sector

Investors have pushed the healthcare sector to a record high, and some favored stocks have high projected revenue growth rates through 2028.

Market Watch • Oct 21, 2026

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study

DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with Type 2 diabetes, supporting CGM adoption.

Zacks Investment Research • Oct 20, 2026

DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives

DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence, especially for non-insulin Type 2 diabetes. The G7 15-Day sensor transition cut manufacturing costs, driving Q2 2026 gross margin up 400 bps to 64.1% and enabling 70% incremental operating margins. CONNECT study results published in NEJM reinforce DXCM's clinical leadership, particularly among GLP-1 users, supporting expanded coverage and future growth.

Seeking Alpha • Oct 18, 2026